HK Stock Announcement Highlights | YUM CHINA Q3 Operating Profit Rises 8% YoY to $400M; SERES Raises HK$14.02B in Global Offering

Stock News

11/04

【Major Updates】 - SCHOLAR EDU (01769) formed a joint venture with Shenzhen Huaxia Junyong to develop AI-powered educational robots. - STARPLUS LEGEND (06683) signed a robot sales contract exceeding RMB 20 million, marking a substantial step in cross-border IP commercialization. - SERES (09927) raised approximately HK$14.02 billion (net proceeds) in its global offering, with its Hong Kong public offering oversubscribed by 132.68 times. - YUM CHINA (09987) reported an 8% year-on-year increase in Q3 operating profit to $400 million and declared a quarterly dividend of $0.24 per share.

【Financial Data】 - YUM CHINA (09987): Q3 operating profit grew 8% YoY to $400 million. - SERES (09927): Global offering net proceeds reached ~HK$14.02 billion. - Other notable updates include clinical trial approvals for a tri-specific antibody therapy and real estate sales figures.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1161169931"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161169931\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161169931?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161169931","market":"hk","top_or_hot":-1,"title":"HK Stock Announcement Highlights | YUM CHINA Q3 Operating Profit Rises 8% YoY to $400M; SERES Raises HK$14.02B in Global Offering","media":"Stock News","content":"<p>【Major Updates】\n- SCHOLAR EDU (01769) formed a joint venture with Shenzhen Huaxia Junyong to develop AI-powered educational robots.\n- STARPLUS LEGEND (06683) signed a robot sales contract exceeding RMB 20 million, marking a substantial step in cross-border IP commercialization.\n- SERES (09927) raised approximately HK$14.02 billion (net proceeds) in its global offering, with its Hong Kong public offering oversubscribed by 132.68 times.  \n- YUM CHINA (09987) reported an 8% year-on-year increase in Q3 operating profit to $400 million and declared a quarterly dividend of $0.24 per share.</p>\n<p>【Financial Data】\n- YUM CHINA (09987): Q3 operating profit grew 8% YoY to $400 million.  \n- SERES (09927): Global offering net proceeds reached ~HK$14.02 billion.  \n- Other notable updates include clinical trial approvals for a tri-specific antibody therapy and real estate sales figures.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Announcement Highlights | YUM CHINA Q3 Operating Profit Rises 8% YoY to $400M; SERES Raises HK$14.02B in Global Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Announcement Highlights | YUM CHINA Q3 Operating Profit Rises 8% YoY to $400M; SERES Raises HK$14.02B in Global Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-04 23:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>【Major Updates】\n- SCHOLAR EDU (01769) formed a joint venture with Shenzhen Huaxia Junyong to develop AI-powered educational robots.\n- STARPLUS LEGEND (06683) signed a robot sales contract exceeding RMB 20 million, marking a substantial step in cross-border IP commercialization.\n- SERES (09927) raised approximately HK$14.02 billion (net proceeds) in its global offering, with its Hong Kong public offering oversubscribed by 132.68 times.  \n- YUM CHINA (09987) reported an 8% year-on-year increase in Q3 operating profit to $400 million and declared a quarterly dividend of $0.24 per share.</p>\n<p>【Financial Data】\n- YUM CHINA (09987): Q3 operating profit grew 8% YoY to $400 million.  \n- SERES (09927): Global offering net proceeds reached ~HK$14.02 billion.  \n- Other notable updates include clinical trial approvals for a tri-specific antibody therapy and real estate sales figures.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2177674079.SGD","symbol_name":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","start_time":0,"source_url":"","article_id":"1161169931","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161169931","pubTimestamp":1762268777,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"【Major Updates】 - SCHOLAR EDU (01769) formed a joint venture with Shenzhen Huaxia Junyong to develop AI-powered educational robots. - STARPLUS LEGEND (06683) signed a robot sales contract exceeding...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601127":"赛力斯","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","IE00BGV7N243.SGD":"FSSA Global Emerging Markets Focus I Acc SGD","YUMC":"百胜中国","BK0185":"二线龙头","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK0264":"汽车制造","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK4504":"桥水持仓","01769":"思考乐教育","BK4209":"餐馆","LU0823426480.USD":"法巴中国股票经典Dis","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK4588":"碎股","BK1596":"K12教育","LU0823426308.USD":"法巴中国股票基金","BK0012":"证金概念","BK1237":"包装食品与肉类","LU0651946864.USD":"贝莱德新兴市场股票收益A2","LU0868486357.SGD":"JPMorgan Funds - Emerging Markets Opportunities A (acc) SGD-H","BK1519":"在线教育","LU0228659784.USD":"施罗德金砖四国基金","IE0003895053.USD":"PINEBRIDGE ASIA DYNAMIC ASSET ALLOCATION \"AD\" USD  ACC","06683":"巨星传奇","LU1051768304.USD":"贝莱德新兴市场股票收益A6","BK0028":"国家队","BK1556":"内地教育股","BK1233":"餐馆","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","IE0034224299.USD":"PINEBRIDGE ASIA EX JAPAN EQUITY \"A\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","09987":"百胜中国","BK0201":"可转债","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","BK1588":"回港中概股","LU0594300419.USD":"富达中国消费基金A","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU2279701549.SGD":"JPMorgan Funds - Emerging Markets Sustainable Equity A (acc) SGD","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","LU1515016050.SGD":"Blackrock Emerging Markets Equity Income A6 SGD-H","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","BK1228":"教育服务","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","09927":"赛力斯","BK4531":"中概回港概念","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","BK4526":"热门中概股","BK0014":"新能源汽车","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU0431992006.USD":"摩根大通新兴市场机会A（acc）","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC"},"translate_title":"港股公告精华|百胜中国Q3营业利润同比增长8%至4亿美元；SERES全球发售集资HK$14.02 B","themeId":"ad31fd92241c03f0c1960e90c772631e","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601127":1,"06683":1,"09987":1,"01769":1,"YUMC":1,"09927":1},"content_text":"【Major Updates】\n- SCHOLAR EDU (01769) formed a joint venture with Shenzhen Huaxia Junyong to develop AI-powered educational robots.\n- STARPLUS LEGEND (06683) signed a robot sales contract exceeding RMB 20 million, marking a substantial step in cross-border IP commercialization.\n- SERES (09927) raised approximately HK$14.02 billion (net proceeds) in its global offering, with its Hong Kong public offering oversubscribed by 132.68 times.  \n- YUM CHINA (09987) reported an 8% year-on-year increase in Q3 operating profit to $400 million and declared a quarterly dividend of $0.24 per share.\n【Financial Data】\n- YUM CHINA (09987): Q3 operating profit grew 8% YoY to $400 million.  \n- SERES (09927): Global offering net proceeds reached ~HK$14.02 billion.  \n- Other notable updates include clinical trial approvals for a tri-specific antibody therapy and real estate sales figures.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}